butenafine

Trade name: mentax

Small moleculeapproved

Approved

Oct 18, 1996

Butenafine is a synthetic antifungal agent that is structurally and pharmacologically related to allylamine antifungals. The exact mechanism of action has not been established, but it is suggested that butenafine's antifungal activity is exerted through the alteration of cellular membranes, which results in increased membrane permeability, and growth inhibition. Butenafine is mainly active against dermatophytes and has superior fungicidal activity against this group of fungi when compared to that of terbinafine, naftifine, tolnaftate, clotrimazole, and bifonazole. It is also active against Candida albicans and this activity is superior to that of terbinafine and naftifine. Butenafine also generates low MICs for Cryptococcus neoformans and Aspergillus spp. as well. Butenafine hydrochloride is marketed under the trade names Mentax, Butop (India) and is the active ingredient in Lotrimin Ultra. MENTAX Cream, 1%, is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (formerly Pityrosporum orbiculare). Although the mechanism of action has not been fully established, it has been suggested that butenafine, like allylamines, interferes with sterol biosynthesis (especially ergosterol) by inhibiting squalene monooxygenase, an enzyme responsible for converting squalene to 2,3-oxydo squalene. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Blockage of squalene monooxygenase also leads to a subsequent accumulation of squalene. When a high concentration of squalene is reached, it is thought to have an effect of directly kill fungal cells. Butenafine cream 1% is indicated in treatment of tinea pedis, tinea corporis and tinea cruris. In tinea pedis it is recommended twice daily for 7 days or once daily for 4 weeks. In tinea cruris and tinea corporis it is recommended once daily for two weeks. — NCATS

Clinical trial activity

10 trials · 8 clinical orgs · 4 marketing orgs

Phase 1
3
Phase 2
6
Phase 3
4
Phase 4
0

Earliest trial started Jun 1, 2008 (NCT00835510)

Timeline

1990s

  1. Oct 18, 1996

    Mylan — Earliest FDA Approval

  2. Oct 18, 1996

    Mylan — NDA Organization

2000s

  1. Dec 7, 2001

    Bayer — NDA Secondary Org

  2. Jan 1, 2008

    Taro Pharmaceuticals — Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Bayer — Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

  3. Nov 16, 2017

    Taro Pharmaceuticals — Marketing Organization

  4. Nov 16, 2017

    Sun Pharmaceuticals — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedOct 18, 1996

Chemistry & pharmacology

Loading structure…

SMILES

CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12
Mol. weight
317.48 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Over the Counter

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine
  • 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine
  • (4-tert-butyl-benzyl)-methyl-naphthalen-1-ylmethyl-amine
  • (4-tert-butyl-benzyl)-methyl-naphthalen-1-ylmethyl-amine
  • (4-tert-butylphenyl)-n-methyl-n-(naphthalen-1-ylmethyl)methanamine
  • (4-tert-butylphenyl)-n-methyl-n-(naphthalen-1-ylmethyl)methanamine
  • butenafina
  • butenafina
  • butenafine
  • butenafine
  • butenafine
  • butenafine
  • butenafine
  • butenafine
  • butenafine
  • butenafine
  • butenafine
  • butenafine hcl
  • butenafine hcl
  • butenafine hcl
  • butenafine hydrochloride
  • butenafine hydrochloride
  • butenafine hydrochloride
  • butenafine hydrochloride
  • butenafine hydrochloride
  • butenafinum
  • butenafinum
  • kp 363
  • kp 363
  • kp-363
  • kp-363
  • kp-363
  • kp-363
  • lotrimin ultra
  • lotrimin ultra
  • mentax
  • mentax
  • mentax
  • mentax
  • mentax-tc
  • mentax-tc
  • n-4-tert-butylbenzyl-n-methyl-1-naphthalene methylamine hydrochloride
  • n-(p-tert-butylbenzyl)-n-methyl-1-naphthalenemethylamine
  • n-(p-tert-butylbenzyl)-n-methyl-1-naphthalenemethylamine
  • s2g6t

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03999437Phase 2Jan 2, 2019United Laboratories Inc
NCT02842021Phase 2Sep 1, 2016Cu-Tech, Sol-Gel Technologies, Ltd.
NCT01990092N/ANov 30, 2013Harvard University, Pamlab
NCT04531540Phase 3Sep 9, 2013Bayer
NCT04531527Phase 3Jun 24, 2013Bayer
NCT04531813Phase 3Jun 10, 2013Bayer
NCT04532164Phase 3Jun 10, 2013Bayer
NCT01580878Phase 1Jan 1, 2012Symbio, Taro Pharmaceuticals
NCT01119742Phase 1Jul 1, 2010Taro Pharmaceuticals
NCT00835510Phase 1Jun 1, 2008Taro Pharmaceuticals
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BayerFor profit4412013
Taro PharmaceuticalsFor profit3312008
Cu-TechFor profit1012016
Harvard UniversityAcademic/Hospital1012013
PamlabFor profit1112013
Sol-Gel Technologies, Ltd.For profit1112016
SymbioFor profit1012012
United Laboratories IncFor profit1112019
8 organizations
Page 1 / 1

Marketing (6)

OrganizationOrg typeRelationshipDate
BayerFor profitNDA2Dec 7, 2001
MylanFor profitSYNOct 18, 1996
MylanFor profitNDAOct 18, 1996
Sun PharmaceuticalsFor profitMKTGNov 16, 2017
Taro PharmaceuticalsFor profitSYNNov 16, 2017
Taro PharmaceuticalsFor profitMKTGNov 16, 2017